ImmunityBio, Inc. is upgraded to Buy reflecting improving Anktiva data & potential label expansions in NMIBC and NSCLC. Read ...
Stocktwits on MSN
IBRX garners retail attention on positive update in immunotherapy for lung cancer patients
The company said that responding patients lived longer overall, with a median survival of 16.2 months. ・The data come from ...
ImmunityBio, Inc. ( IBRX) 44th Annual J.P. Morgan Healthcare Conference January 11, 2026 7:00 PM EST ...
Implementing Deep Inspiration Breath-Hold (DIBH) for Left-Sided Breast Cancer Radiotherapy at the Anbar Cancer Center, Iraq: ...
Blood eosinophil count at a specific threshold shows high sensitivity and specificity for diagnosing eosinophilic ...
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA ...
ANKTIVA, in combination with an immune checkpoint inhibitor, has received accelerated approval from the Saudi Food and Drug ...
Brigham and Women's Hospital investigators link very high lipoprotein(a) with a higher 30-year risk of major cardiovascular ...
Cervical lymphadenopathy presents a shared anatomic challenge for clinicians, yet it serves as the divergent starting point ...
Of all the types of breast cancer, triple negative breast cancer (TNBC) is the most aggressive and lacks specific therapies.
Background Autoimmune neutropenia (AIN) is the main cause of chronic neutropenia in children, but its infectious consequences ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback